Clinical Trial Detail

NCT ID NCT02974803
Title Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Canadian Cancer Trials Group
Indications

melanoma

Therapies

Dabrafenib + Trametinib

Age Groups: senior adult

Additional content available in CKB BOOST